References
- National Center for Biotechnology Information. PubChem Compound Summary for CID 644019, Cannabidiol 2022. [cited 2022 March 13]. https://pubchem.ncbi.nlm.nih.gov/compound/Cannabidiol
- Hanus LO, Tchilibon S, Ponde DE, et al. Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem. 2005;3(6):1116–1123.
- Mead A. Legal and regulatory issues governing cannabis and Cannabis-Derived products in the United States. Front Plant Sci. 2019;10:697.
- US Food and Drug Administration. Approval letter. Epidiolex®; GW Research, Ltd. 2022. [cited 2022 March 13]. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210365Orig1s000Ltr.pdf
- US Food and Drug Administration. Package insert. Epidiolex®; GW Research, Ltd. 2022 [cited 2022 March 13]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210365s015lbl.pdf
- Leas EC, Hendrickson EM, Nobles AL, et al. Self-reported cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw Open. 2020;3(10):e2020977.
- US Food and Drug Administration. Warning Letters and Test Results for Cannabidiol-Related Products. 2022. [cited 2022 March 13]. https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products
- Kachru R, Perry-Lunardo C, Thompson LA. CBD use in Children-Miracle, myth, or mystery? JAMA Pediatr. 2021;175(6):652.
- Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual report of the American association of poison control centers’ national poison data system (NPDS): 38th annual report. Clin Toxicol (Phila). 2021;59(12):1282–1501.
- Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual report of the American association of poison control centers’ national poison data system (NPDS): 37th annual report. Clin Toxicol (Phila). 2020;58(12):1360–1541.
- Rubin R. Cannabidiol products are everywhere, but should people be using them? JAMA. 2019;322(22):2156–2158.
- Dilley JA, Graves JM, Brooks-Russell A, et al. Trends and characteristics of manufactured cannabis product and cannabis plant product exposures reported to US poison control centers, 2017-2019. JAMA Netw Open. 2021;4(5):e2110925.
- Laudone TW, Leonard JB, Hines EQ, et al. Changes in unintentional cannabis exposures in children 6 months to 5 years reported to United States poison centers during the first nine months of the coronavirus-19 pandemic. Clin Toxicol (Phila). 2022;60(9):1029–1031.
- Leonard JB, Laudone T, Hines EQ, et al. Critical care interventions in children aged 6 months to 12 years admitted to the pediatric intensive care unit after unintentional cannabis exposures. Clin Toxicol (Phila). 2022;60(8):960–965.
- Myran DT, Cantor N, Finkelstein Y, et al. Unintentional pediatric cannabis exposures after legalization of recreational cannabis in Canada. JAMA Netw Open. 2022;5(1):e2142521. Jan 4
- Radhakrishnan L, Carey K, Hartnett KP, et al. Pediatric emergency department visits before and during the COVID-19 Pandemic - United States, january 2019-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(8):313–318.
- Whitehill JM, Harrington C, Lang CJ, et al. Incidence of pediatric cannabis exposure among children and teenagers aged 0 to 19 years before and after medical marijuana legalization in Massachusetts. JAMA Netw Open. 2019;2(8):e199456. Aug 2
- Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8(7):989.
- US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program 2022. [cited 2022 March 13]. Available from: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
- US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Questions and Answers 2022. [cited 2022 March 13]. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
- Karami S, Perez-Vilar S, Leishear K. Cannabidiol exposure calls to U.S Poison Control Centers. Pharmacoepidemiol Drug Saf. 2020;29(Suppl 3):499.
- Berger BA, Stolz U, Colvin J, et al. Epidemiology of cannabidiol related cases reported in the national poison data system – 2019-2020. Am J Emerg Med. 2021;48:218–223.
- Karami S, Major JM, Calderon S, et al. Trends in dextromethorphan cough and cold products: 2000-2015 national poison data system intentional abuse exposure calls. Clin Toxicol (Phila). 2018;56(7):656–663.